Enliven Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-103.7M | $-89.0M | $-71.6M | $-37.7M | $-51.4M | $-41.4M | $-23.5M |
| Depreciation & Amortization | $300.0K | $300.0K | $300.0K | $200.0K | — | — | — |
| Depreciation | $263.0K | $317.0K | $297.0K | $215.0K | $99.0K | $97.0K | $33.0K |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $34.0M | $20.2M | $12.9M | $3.2M | $3.8M | $2.2M | $899.0K |
| Net Cash from Operating Activities | $-70.3M | $-73.2M | $-61.3M | $-32.1M | $-46.8M | $-37.4M | $-21.9M |
| Investing Activities | |||||||
| Capital Expenditures | $158.0K | $44.0K | $149.0K | $612.0K | $12.0K | $18.0K | $140.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-173.8M | $-36.0M | $-148.4M | $-612.0K | $-1.6M | $-16.7M | $-24.1M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $218.9M | $133.2M | $234.3M | $-1.8M | $49.1M | $96.9M | $43.6M |
| Net Change in Cash | — | — | — | — | — | — | — |
| Free Cash Flow | $-70.5M | $-73.2M | $-61.4M | $-32.7M | $-46.8M | $-37.4M | $-22.0M |